PEAL CAPITAL GROUP LIMITED

Peal Capital Group Limited is a specialist private-equity firm focused exclusively on the longevity and hormones sector. Drawing on more than 65 years of combined industry experience, the firm partners with management teams across Western Europe, the United Kingdom and North America to unlock hidden value in mature lower-mid-cap businesses. By taking controlling or influential minority stakes, Peal provides hands-on operational and financial support from acquisition through to exit, aiming to accelerate growth and deliver strong, risk-adjusted returns.

The group's three-fund strategy spans the entire supply chain, giving investors access to proprietary, off-market opportunities and full-spectrum exposure. Its disciplined approach is underpinned by deep due-diligence that relies on live portfolio data rather than projections, targeted exit strategies that shorten holding periods, and a strong alignment of interests with both management teams and investors. With 58 direct investments to date and an average multiple of 2.27 times cost, Peal Capital demonstrates a proven track record of consistent performance while upholding values of integrity, transparency and long-term partnership.